Navigation Links
Mount Sinai Researchers Find that Blocking Sugar Intake May Reduce Cancer Risk or Progression in Obese and Diabetic People
Date:8/1/2013

New York, NY (PRWEB) August 01, 2013

Blocking dietary sugar and its activity in tumor cells may reduce cancer risk and progression, according to researchers from the Icahn School of Medicine. The study, conducted in fruit flies and published in the journal Cell, provides insight as to why metabolism-related diseases such as diabetes or obesity are associated with certain types of cancer, including pancreatic, breast, liver, and colon cancers.

Ross Cagan, PhD, Professor of Developmental and Regenerative Biology at Mount Sinai, has developed a cancer model in the fruit fly Drosophila that allows scientists to evaluate diseases in the context of the whole animal and multiple genetic targets, rather than just looking at the connection of one gene to one disease. In the current study, Dr. Cagan used fruit flies to understand the effects of diet and insulin resistance on cancer progression.

Cells use glucose for energy and to grow. When a cell becomes insulin resistant, glucose builds up in the blood instead of being absorbed by the cell, starving the cell and leading to metabolic diseases like diabetes. Because of this dysfunctional growth, scientists have been puzzled about how tumors can thrive in an insulin-resistant environment.

“Previous research has established a strong correlation between metabolic diseases and pancreatic, breast, liver, and colon cancers, but we have not determined how tumors grow so aggressively in this environment if they do not have the energy provided by glucose,” said Dr. Cagan, who is also Associate Dean of the Graduate School of Biomedical Sciences at Mount Sinai. “Using our fruit fly model, we discovered how tumors overcome insulin resistance in the body and turn metabolic dysfunction to their advantage.”

Dr. Cagan and his team engineered fruit flies to express Ras and Src, two important oncogenes, resulting in the development of small head tumors. Next, they fed the flies with a high-sugar diet that promoted insulin resistance. They found that high dietary sugar acts together with Ras and Src to increase insulin sensitivity specifically in tumor cells. By ramping up signaling of an important pathway called Wingless/Wnt, they increased tumor cells’ insulin receptors to further promote insulin sensitivity. This cascade of activity changed these small, weak tumors and caused them to begin growing aggressively.

Armed with three new drug targets—glucose, the Ras/Src oncogenes, and Wingless/Wnt signaling—Dr. Cagan and his team identified compounds that can block the process. They treated the flies with acarbose, a treatment for diabetes; a compound called AD81; and a drug called pyrvinium. Acarbose blocked sugar conversion to glucose; AD81 cut off Ras/Src and caused cell death; and pyrvinium inhibited Wingless/Wnt signaling. Taken together, this cocktail of drugs substantially reduced tumor size and progression.

“Our study shows that sugar activates oncogenes in the tumor, which then promote insulin sensitivity, meaning that the exorbitant glucose levels in the blood pour into the tumor, having nowhere else to go in the insulin-resistant body,” said Dr. Cagan. “We have identified a three-drug combination that stops this signaling activity and tumor growth in its tracks, without affecting normal cell function.”

Next, the research team plans to find out whether the same cascade of events is happening in humans with insulin resistance using tumor samples. Based on those findings, Dr. Cagan and his team will test compounds that exploit this oncogene/sugar cascade.

This work was supported through multiple grants from the National Institutes of Health.

###

Read the full story at http://www.prweb.com/releases/2013/8/prweb10986577.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mountain Trek Announces Their Annual Hiking Vacation Will be a Trek through Southern Japan
2. Paramount Direct Marketing Is Excited to Announce a New Marketing List Under Management: AAA Pre-Mover
3. Mount Sinai launches first-ever genetic testing program in the primary care setting
4. The Mount Sinai Medical Center Launches Real-Time Patient-Feedback Survey Tool
5. United Benefit Advisors Names Mountain West Benefits “Partner Firm of the Year”
6. Air-Care Releases Ultraviolet Air Purifier Light That Mounts in the Air Ducts
7. Stryker Recall News: Filings Mount in New Jersey Litigation Established for Stryker Hip Lawsuits, Bernstein Liebhard LLP Reports
8. Hardware Manufacture Custom Car Docks Adopts Apple’s New Philosophy of Simple Clean Lines, in Their iPhone Car Mount
9. Mount Sinai researchers discover mechanism behind development of autoimmune hepatitis
10. Mountain States Health Alliance Selects BESLER Consulting’s Revenue Recovery Services
11. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and ... creation of published authors, Bob and Margaret Massey. Bob Massey is small in stature ... and leather tough." His love for others is apparent in all of his life ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last ... Mary Ellen, hospital employees, and town officials to celebrate the grand opening of ... developed by Rendina as part of its ongoing relationship with RWJBarnabas Health, New ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... dental implants in Bayside, NY, who have now spent 10 years as clinical ... New York University (NYU) College of Dentistry. Through the program, private practitioners receive ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Curry Leavitt, a ... (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate and dedicated clinician, ... by attending numerous CE courses each year. His recent course, Course II of ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... pediatric dentistry options for its patients on Long Island, New York. , ... well being, and is one of the biggest trends in dentistry today. ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... BURNIE, Md. , May 10, 2017 ... retention solutions for the clinical research industry, is proud ... www.CSSiEnroll.com . The new website features both enriched ... overall user experience and enhances the company,s already well-established ... the industry. "After many months of ...
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
Breaking Medicine Technology: